Amgen Inc. $AMGN Shares Acquired by National Pension Service

Key Points

• National Pension Service boosted its Amgen stake by 4.7% in the fourth quarter, ending with 1.24 million shares valued at about $405.7 million.
• Amgen reported better-than-expected Q1 earnings, posting $5.15 EPS versus $4.77 expected, while revenue rose 5.8% year over year to $8.62 billion.
• The company declared a quarterly dividend of $2.52 per share, equal to an annualized yield of about 3.0%, even as analyst ratings remain mixed with a consensus Hold and average price target of $355.19.

National Pension Service increased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,239,549 shares of the medical research company's stock after purchasing an additional 55,489 shares during the quarter. National Pension Service owned about 0.23% of Amgen worth $405,717,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of AMGN. Brighton Jones LLC raised its position in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after acquiring an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC raised its position in Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company's stock worth $331,000 after acquiring an additional 114 shares in the last quarter. Schnieders Capital Management LLC. raised its position in Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company's stock worth $7,220,000 after acquiring an additional 5,853 shares in the last quarter. Main Street Financial Solutions LLC raised its position in Amgen by 11.3% in the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company's stock worth $1,141,000 after acquiring an additional 416 shares in the last quarter. Finally, Ieq Capital LLC raised its position in Amgen by 5.1% in the second quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company's stock worth $15,120,000 after acquiring an additional 2,611 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Trading Up 0.1%

NASDAQ:AMGN opened at $336.48 on Friday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The stock's 50-day moving average is $342.83 and its two-hundred day moving average is $345.39. The stock has a market cap of $181.60 billion, a PE ratio of 23.42, a price-to-earnings-growth ratio of 3.37 and a beta of 0.44.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion for the quarter, compared to analysts' expectations of $8.58 billion. During the same quarter in the previous year, the business posted $4.90 EPS. The business's revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts forecast that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's payout ratio is 70.15%.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company's stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.85% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on AMGN shares. The Goldman Sachs Group boosted their price target on shares of Amgen from $415.00 to $425.00 and gave the stock a "buy" rating in a research report on Friday, May 1st. Wall Street Zen upgraded shares of Amgen from a "hold" rating to a "buy" rating in a research report on Saturday, May 23rd. Citigroup boosted their price target on shares of Amgen from $315.00 to $345.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 4th. Canaccord Genuity Group started coverage on shares of Amgen in a research report on Monday, April 20th. They issued a "hold" rating and a $366.00 price target on the stock. Finally, Royal Bank Of Canada boosted their price target on shares of Amgen from $360.00 to $370.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 7th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Amgen currently has an average rating of "Hold" and a consensus price target of $355.19.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.